[Two classes of medicine: what are the consequences of treatment advances with new recombinant proteins?].
Dingermann
Theodor
T
Schubert-Zsilavecz
Manfred
M
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001709:Biotechnology; D010600:Pharmacology / Q000639:trends*; D011994:Recombinant Proteins / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D011994:Recombinant Proteins